Wright & Schulte LLC Notes Additional Testim lawsuit filed on behalf of a Louisiana Man Who Suffered Multiple Strokes After Using the “Low T” Treatment Drug
Another Testim lawsuit, this one filed in Louisiana (case no.2-14-cv-00839), is claiming low testosterone therapy is behind the multiple strokes suffered by a Jefferson Parish man. Wright & Schulte LLC recently learned of the Testim lawsuit while investigating other Testim and Adrogel Lawsuit (In Re: AndroGel Product Liability Litigation, MDL Docket No. 36). This Testim lawsuit alleged the use of AndroGel and Testim caused the plaintiff to suffer two strokes. The testosterone treatment complaint, filed April 10, 2014, in U.S. District Court for the Eastern District of Louisiana, seeks damages from AbbVie Inc. and Abbot Laboratories, which manufactures and markets AndroGel, and Auxilium Pharmaceuticals, Inc., the maker of Testim. The complaint accuses the companies of misrepresenting their products as safe, easy to use and free from serious side effects. (case no. 2-14-cv-00839000
According to court documents, the plaintiff experienced symptoms to which he attributed to low testosterone based on the defendants’ advertisements. The plaintiff stated in the low testosterone therapy lawsuit that he was prescribed AndroGel and Testim in 2006 when he was 63 years old and continued taking the topical gel products until 2014. The Testim lawsuit further stated in his complaint that prior to taking the testosterone treatment, he had not had cardiac problems and had he known about the risks associated with the therapy, he would not have had to suffer the serious side effects of the medication. The AndroGel and Testim lawsuit cited a study published in the August 2013 issue of the American Medical Association which found that men who were prescribed testosterone treatment had no evidence of low testosterone, also known as hypogonadism.
Testosterone Drugs Under Scrutiny by FDA
The U.S. Food & Drug Administration (FDA) approved AndroGel in February 2000, and Testim in October 2002, for use in men who had low testosterone or who could no longer produce testosterone. In May 2009, the agency required the makers of the two prescription drugs to include boxed warnings on the labels of the two topical gel products after receiving reports that children have adverse effects when they are inadvertently exposed to the medication through contact with someone who was taking testosterone replacement therapy. By January 31, 2014, the FDA announced that it was launching an investigation into testosterone replacement therapies based on two studies that found older men or men with pre-existing heart conditions who use these drugs, might be at a higher risk of having strokes, heart attacks and even death.
[fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/ucm189806.htm], 2009; [fda.gov/Drugs/DrugSafety/ucm383904.htm], January 31, 2014
According to court documents, this Testim complaint follows three similar Testim lawsuits filed in the Philadelphia Court of Common Pleas in March over Testim. An Alabama man stated in his lawsuit, filed March 12, 2014, that the testosterone gel caused him to suffer neurologic impairment and cognitive deficits and impairment.
In the second complaint, filed March 18, 2014, a plaintiff from New Jersey alleged that he had a heart attack as a result of using Testim. In the third complaint, filed March 21, a Pennsylvania resident alleged that he had to have heart bypass surgery due to using Testim and AndroGel.
(Case No. 140301684); [Case No. 140302537]; [Case No.140303508]
Also in March, plaintiffs in federal testosterone replacement therapy lawsuits asked the U.S. Judicial Panel on Multidistrict Litigation in a petition to consolidate all federally filed AndroGel lawsuits in the Northern District of Illinois. The plaintiffs alleged in their complaints that taking AndroGel caused them to have strokes, heart attacks and other health problems. [In Re: AndroGel Product Liability Litigation, MDL Docket No. 36].